الفهرس 
LITERATURE REVIEWOnly 14 pages are availabe for public view
 |  | from | 58 |  |  |
| | | from | 58 | | |
Abstract
Human parvovirus B19 was discovered by chance in 1975 by Cossart. It is the only
member of the family of parvoviridae that is known to be pathogenic in man. Parvovirus
B19 is one of the emerging transfusion transmissible infections.
Transmission of parvovirus B19 is through respiratory droplets or during pregnancy.
Because the virus is present in high titer in serum, transmission from blood products had
occurred. Parvovirus B19 infection is common, it has worldwide distribution and any age
can be affected, frequently among preschool and school age children.
Most cases of parvovirus B19 infection are asymptomatic. The most common
clinical presentation of infection is erythema infectiosum, or fifth disease. Parvovirus B19
is also associated with an increasing range of different diseases. These include acute and
chronic arthritis, hydrops fetalis in pregnant women, chronic red cell aplasia, transient
aplastic crisis and thrombocytopenia especially in patients with chronic hematological
disorders requiring multiple blood transfusions.
The aim of this study was screening for parvovirus B19 antibodies among repeated
blood transfusion recipients and to compare between their levels to those of healthy
donors.
Forty five multiple blood transfusion recipients and 45 healthy blood donors as a
control group were included in the study. Their age ranged from18 to 60 years. Blood
samples were collected from all participants, sera were separated and used for
determination of the levels of parvovirus B19 IgG by ELISA technique.
from this study, the following results were obtained:
1- The mean age of the multitransfused patients was 29.73 ± 7.16 years, while it was
29.24 ± 29.24 years among the control group.
2- Males represented 73.3% and 88.9% of the multitransfused patients and controls
respectively.
3- Regarding the history of clinical symptoms that can be related to parvovirus B19
infection, fever, rash and arthritis were reported in 62.2%, 60% and 22.2% of
multitransfused patients respectively and in 31.1%, 2.2% and 22.2% of control group
respectively.
4- Parvovirus B19 IgG were found among 53.3% of multitransfused patients with a mean
titer of 20.42 ± 20.69 DU and among 31.1% of the control group with a mean titer of
10.44 ± 8.59 DU. These results were statistically significant.
Conclusion:
from the present study, it can be concluded that:
1- The positivity rates and levels of parvovirus B19 IgG were significantly higher among
multitransfused patients than among control group.
2- There was significant statistical difference in the occurrence of fever and rash between
multitransfused patients and control group.
Summary & Conclusion
33
3- There were no significant statistical relations between the positivity of parvovirus B19
IgG and age, sex and history of clinical symptoms except rash.
4- The type of the disease requiring multiple transfusions between the studied groups had
no effect on the levels of parvovirus B19 IgG.